Pharmaceuticals giant AstraZeneca has announced that it has agreed to acquired California-based biotechnology company Ardea Biosciences, whose lead product 'Lesinurad' (RDEA594) is currently in Phase III development as a potential treatment for the chronic management of hyperuricaemia in patients with gout.
"This attractive Phase III programme is an excellent opportunity to leverage AstraZeneca's global specialty and primary care sales and marketing capabilities," said David Brennan, Chief Executive Officer of AstraZeneca.
Under the terms of the definitive merger agreement, Astra will pay $32 per Ardea shares, representing a total cash value of around $1.26bn, including existing cash. This is a 55% premium to Ardea's closing price on Friday April 20th.
Subscribe to MoneyWeek
Subscribe to MoneyWeek today and get your first six magazine issues absolutely FREE
Sign up to Money Morning
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
The boards of both companies have unanimously approved the terms of the agreement and the transaction is expected to complete in the second or third quarter of 2012, according to Astra's statement on Monday.
BC
-
Side hustle tax changes: HMRC reforms could save thousands from filing self-assessment tax returnsThe government plans to raise the tax-free threshold for trading income – here is how it could help your side hustle
-
Return to the office: is working from home coming to an end?More and more employers want their staff to return to the office. Is it a good idea?
